MRSA or Methicillin Resistant Staph Aureus is known to cause infections such as skin and soft tissue infections, wounds (traumatic), Osteomyelitis, Bacteremia etc. The risk factors for someone to get infected includes recurrent skin disease, open wound, illicit drug use, surgery, recent hospitalization, living in crowded setting, long term illness or dialysis patient. The current standard therapy for MRSA includes vancomycin. The treatment with vancomycin requires frequent monitoring of drug levels, renal function and dose adjustments. There are cases that showed bacteria becoming resistant to vancomycin as well.
The manufacturer reported dalbavancin as a new approach towards MRSA treatment. Dalbavancin is the first once weekly lipo-glycopeptide antibiotic. It is only used in adult patients and dosed as 1000mg IV on day 1 and 500 mg IV on day 8. The drug should be infused over 30 minutes to prevent infusion related adverse effects. The dose is required to be reduced to 750 mg on day 1 and 375 mg on day 8 for patients with compromised renal function (Crcl <30ml/min)
Some common adverse effects includes constipation, nausea, headache, pruritis and diarrhea. Some serious side effects (<2%) includes GI hemorrhage, hepatotoxicity and infusion related reactions.
The clinical trials showed that Delbavancin is non-inferior when compared to Vancomycin/Linezolid therapy in Acute bacterial Skin and Skin Structure Infection (ABSSSI Trial).
Click here for more information on Dalbavancin.
Posted by: Kamaldeep Kainth, PharmD candidate 2015